<DOC>
	<DOCNO>NCT00182715</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether combination chemotherapy cetuximab effective combination chemotherapy alone treat colorectal cancer . PURPOSE : This randomized phase III trial study combination chemotherapy cetuximab see well work compare combination chemotherapy alone first-line therapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Cetuximab First-Line Therapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient metastatic colorectal adenocarcinoma treat continuous combination chemotherapy comprise oxaliplatin , leucovorin calcium , fluorouracil ( OxMdG ) oxaliplatin capecitabine ( XELOX ) v without cetuximab v intermittent combination chemotherapy OxMdG XELOX first-line therapy . Secondary - Compare time disease control progression- failure-free survival patient treat regimen . - Compare response patient treat regimen . - Compare toxicity regimens patient . - Compare cost effectiveness regimens patient . - Compare quality life patient treat regimen . OUTLINE : This multicenter , open label , randomize , control study . Patients randomize 1 3 treatment arm . - Arm I ( continuous chemotherapy ) : Patients receive 1 follow combination chemotherapy regimens choice ( per participate center ) : - OxMdG : Patients receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour day 1 2 . Courses repeat every 14 day absence disease progression unacceptable toxicity . - XELOX : Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . - Arm II ( continuous chemotherapy cetuximab ) : Patients receive OxMdG XELOX arm I . Patients also receive cetuximab IV 1-2 hour day 1 8 ( patient receive OxMdG ) OR day 1 , 8 , 15 ( patient receive XELOX ) . Treatment OxMdG cetuximab repeat every 14 day absence disease progression unacceptable toxicity . Treatment XELOX cetuximab repeat every 21 day absence disease progression unacceptable toxicity . - Arm III ( intermittent chemotherapy ) : Patients receive OxMdG XELOX arm I . Treatment OxMdG repeat every 14 day 6 course ( 12 week ) . Treatment XELOX repeat every 21 day 4 course ( 12 week ) . Patients disease progression 12 week therapy remove study treatment . Patients stable respond disease 12 week therapy stop treatment undergo clinical evaluation least every 6 week ( treatment break ) disease progression clinical deterioration . Upon evidence disease progression clinical deterioration , patient restart treatment OxMdG XELOX continue alternate 12 week treatment treatment break absence disease progression unacceptable toxicity Quality life assess baseline , 6 week , 12 week , every 12 week thereafter . After completion study treatment , patient follow every 12 week survival . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 2,421 patient ( 807 per treatment arm ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colorectal adenocarcinoma , define 1 following : Histologically confirm primary adenocarcinoma colon rectum clinical radiological evidence advance and/or metastatic disease Histologically cytologically confirm metastatic adenocarcinoma clinical radiological evidence primary colorectal tumor Unidimensionally measurable disease Inoperable metastatic locoregional disease Ineligible hepatic resection firstline combination chemotherapy No brain metastases PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.25 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN AST ALT ≤ 2.5 time ULN Renal Creatinine clearance glomerular filtration rate ≥ 50 mL/min Cardiovascular No poorly control angina No myocardial infarction within past 3 month Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception Must consider fit undergo combination chemotherapy No psychiatric neurological condition would preclude study compliance give informed consent No partial complete bowel obstruction No malignant disease would preclude study treatment No preexisting neuropathy &gt; grade 1 No know hypersensitivity reaction component study drug No known DPD deficiency personal family history suggestiv DPD deficiency No severe uncontrolled medical illness would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic palliative chemotherapy metastatic disease No prior oxaliplatin More 1 month since prior adjuvant fluorouracil ( 5FU ) ( without leucovorin calcium ) , capecitabine , irinotecan More 1 month since prior rectal chemoradiotherapy 5FU ( without leucovorin calcium ) capecitabine Endocrine therapy Not specify Radiotherapy See Chemotherapy Surgery Not specify Other No concurrent brivudine sorivudine ( patient receive capecitabine study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>